1. Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome

3. Cost of Heart Failure to Society

4. Challenges/Opportunities for Utilizing Biomarkers in the Management of Heart Failure

5. BNP and NT-proBNP for Diagnosis or Exclusion of Heart Failure

6. Correlations of Natriuretic Peptides With Cardiac Structure and Function

7. The Differential Diagnosis of an Elevated BNP or NT-proBNP

8. BNP and NT-proBNP for Prognosis in Heart Failure

9. BNP/NT-proBNP and Stage C HF Prognosis

10. The Importance of Serial NP Measurements for Prognostication in Chronic HF

11. IMPROVE HR: Improvements in Quality Measures at 24 Months (Patient Level Analysis)

12. Therapies With Effects on B-Type Natriuretic Peptide Levels

13. Biomarker-Guided Heart Failure Trials

14. Understanding Heterogeneous Results in “Guided Therapy” Trials

15. TIME CHF: Cost Effectiveness

16. Emerging Uses of Natriuretic Peptides to Guide Therapy

17. Emerging Biomarkers in Heart Failure

18. Biomarkers for Detection of Myocardial Infarction

19. Diagnostic Performance of Sensitive Assays for Troponin

20. Elevations of Cardiac Troponin Values Because of Myocardial Injury

21. Elevations of Cardiac Troponin Values Because of Myocardial Injury

23. Universal Classification of Myocardial Infarction

24. Universal Classification of Myocardial Infarction (cont)

25. Prognostic Use of a Sensitive Current Generation Assay for cTn

26. cTnl Assay Problems

27. Elevations of Troponins Without Overt Ischemic Heart Disease

28. Abbreviations

29. Abbreviations

30. Abbreviations